35). In multivariate regression (Table 5), individuals with a significantly reduced Nutlin 3 risk of a liver-related death included those with an SVR, compared to a non-SVR (AHR: 0.22; 95% CI: 0.09-0.58), whereas those with a significantly increased risk of a liver-related hospital episode included those
older in age at study entry (linear increase over <30, 30-39, 40-49, 50-59, and >=60 years age group categories: 1.70; 95% CI: 1.27-2.29), diagnosed cirrhotic (3.63; 95% CI: 1.99-6.60), and with an alcohol-related hospitalization during FU (6.82; 95% CI: 3.79-12.26). Our results did not significantly differ when a liver-related death was defined on the basis of the main cause of death only. Adjusted liver-related SMBRs (Tables 6 and 7) were higher when the main and supplementary discharge codes were collectively considered, compared to when only the main discharge code was considered. Adjusted liver-related SMBRs were highest among individuals
with a non-SVR—up to 53 (based on main and supplementary codes: 53.17; 95% CI: 49.43-57.23) times greater than that of the general Scottish population. They were lowest among noncirrhotic SVR patients, but still between two times (based on main discharge code[s] only: 2.19; 95% CI: 1.12-4.92) and six times (based on main and supplementary codes: 5.92; https://www.selleckchem.com/products/AC-220.html 95% CI: 4.49-7.95) greater than the general Scottish population. Furthermore, there was no evidence that the risk of an alcohol-related hospital episode in noncirrhotic SVR patients differed from that of the general population (based on main and supplementary codes: 1.26; 95% CI: 0.89-1.84). The risk of a liver-related hospital episode in patients who had spontaneously resolved their HCV infection was between 18 (based on main discharge code[s] only: 18.25; 95% CI: 16.52-20.20) and 27 (based on main and supplementary discharge codes: 26.75; 95% CI: 25.29-28.31) times greater than that of the general Scottish population. Furthermore, their risk of an alcohol-related hospitalization was up to 10 times higher
than the general population (based on main MTMR9 and supplementary codes: 9.50; 95% CI: 8.64-10.48). In terms of non-liver-related morbidity, SMBRs for non-liver-related hospital episodes in all SVR patients were between 29% (based on main and supplementary discharge codes) and 41% (based on main code[s] only) lower than that of non-SVR patients. In a post-HCV treatment cohort with a mean patient FU of 5.3 years, our analyses show that treatment-naïve patients attaining a SVR were five times less likely both to die a liver-related death (AHR: 0.22; 95% CI: 0.09-0.58) and experience a liver-related hospital episode (0.22; 95% CI: 0.15-0.34), compared to patients not attaining an SVR. The size of this SVR effect was considerable and is consistent with other studies.